News Daily News Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs Michael O'Riordan November 27, 2023
News Daily News Etripamil Continues to Show Promise in Paroxysmal SVT: NODE-302 Caitlin E. Cox September 27, 2023
News Daily News Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis Todd Neale June 05, 2023
News Daily News Initiative Lowers Unnecessary Aspirin Use in Warfarin Users Todd Neale September 26, 2022
News Features Roughly 80% of ESC Guideline Writers Have Financial COIs Michael O'Riordan April 01, 2021
News Conference News HRS 2020 PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety Todd Neale May 15, 2020
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
News Conference News ISC 2019 Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects Todd Neale February 13, 2019
News Daily News Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines Todd Neale January 29, 2019
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Daily News DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus Caitlin E. Cox October 04, 2018
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017